Thrombophilia and the risk for hemodialysis vascular access thrombosis

Journal of the American Society of Nephrology

Volumn 16, Issue 4, 2005, Pages 1108-1114

  Knoll, Greg A ^a,b,d   Wells, Philip S ^a,b   Young, Darlene ^b   Perkins, Sherry L ^a   Pilkey, Rachel M ^c   Clinch, Jennifer J ^b   Rodger, Marc A ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LIPOPROTEIN; LUPUS ANTICOAGULANT; PROTHROMBIN;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENOTYPE; HEALTH CENTER; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; VASCULAR ACCESS; ARTERIOVENOUS SHUNT; CONFIDENCE INTERVAL; GRAFT OCCLUSION; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK;

AGED; ARTERIOVENOUS SHUNT, SURGICAL; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RENAL DIALYSIS; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 24344491537     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110999     Document Type: Article

References (48)

1. US Renal Data System: Excerpts from the USRDS 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 42: S1-S230, 2003
2. Feldman HI, Kobrin S, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7: 523-535, 1996
3. Schwab SJ: Vascular access for hemodialysis. Kidney Int 55: 2078-2090, 1999
4. Casserly LF, Dember LM: Thrombosis in end-stage renal disease. Semin Dial 16: 245-256, 2003
5. Schwab SJ: Hemodialysis vascular access: An ounce of prevention. Kidney Int 52: 1704-1705, 1997
6. Schwab SJ, Oliver MJ, Suhocki P, McCann R: Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 59: 358-362, 2001
7. Moist LM, Churchill DN, House AA, Millward SF, Elliot JE, Kribs SW, Deyoung WJ, Blythe L, Stitt LW, Lindsay RM: Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 14: 2645-2653, 2003
8. Tessitore N, Mansueto G, Bedogna V, Lipari G, Poli A, Gammaro L, Baggio E, Morana G, Loschiavo C, Laudon A, Oldrizzi L, Maschio G: A prospective controlled trial on effect of percutaneous transluminal angioplasty on functioning arteriovenous fistulae survival. J Am Soc Nephrol 14: 1623-1627, 2003
9. Tripodi A, Mannucci PM: Laboratory investigation of thrombophilia. Clin Chem 47: 1597-1606, 2001
10. Paulson WD: Prediction of hemodialysis synthetic graft thrombosis: Can we identify factors that impair validity of the dysfunction hypothesis? Am J Kidney Dis 35: 973-975, 2000
11. Nampoory MR, Das KC, Johny KV, Al Hilali N, Abraham M, Easow S, Saed T, Al Muzeirei IA, Sugathan TN, Al Mousawi M: Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 42: 797-805, 2003
12. O'shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL: Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38: 541-548, 2003
13. Fukasawa M, Matsushita K, Kamiyama M, Mikami Y, Araki I, Yamagata Z, Takeda M: The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 41: 637-642, 2003
14. Atac B, Yakupoglu U, Ozbek N, Ozdemir FN, Bilgin N: Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc 34: 2030-2032, 2002
15. Shemin D, Lapane KL, Bausserman L, Kanaan E, Kahn S, Dworkin L, Bostom AG: Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 10: 1095-1099, 1999
16. Hernandez E, Praga M, Alamo C, Araque A, Morales JM, Alcazar JM, Ruilope LM, Rodicio JL: Lipoprotein(a) and vascular access survival in patients on chronic hemodialysis. Nephron 72: 145-149, 1996
17. Valeri A, Joseph R, Radhakrishnan J: A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 51: 116-121, 1999
18. LeSar CJ, Merrick HW, Smith MR: Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 189: 73-81, 1999
19. Palomo I, Pereira J, Alarcon M, Vasquez M, Pierangeli S: Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron 92: 957-958, 2002
20. Hojs R, Gorenjak M, Ekart R, Dvorsak B, Pecovnik-Balon B: Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 24: 215-222, 2002
21. Adler S, Szczech L, Qureshi A, Bollu R, Thomas-John R: IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 56: 428-434, 2001
22. Fodinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Horl WH, Sunder-Plassmann G: Resistance to activated protein C (APC): Mutation at ARG of coagulation factor V and vascular access thrombosis in hemodialysis patients. Nephrol Dial Transplant 11: 668-672, 1996
23. Miller CD, Robbin ML, Barker J, Allon M: Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. J Am Soc Nephrol 14: 2942-2947, 2003
24. Ram SJ, Work J, Caldito GC, Eason JM, Pervez A, Paulson WD: A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int 64: 272-280, 2003
25. Lok CE, Bhola C, Croxford R, Richardson RM: Reducing vascular access morbidity: A comparative trial of two vascular access monitoring strategies. Nephrol Dial Transplant 18: 1174-1180, 2003
26. Mas VR, Fisher RA, Maluf DG, Archer KJ, Contos MJ, Mills SA, Shiftman ML, Wilkinson DS, Oliveros L, Garrett CT, Ferreira-Gonzalez A: Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet 65: 191-201, 2004
27. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA: New generation pharmacogenomic tools: A SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques 32: S48-S54, 2002
28. Kyrie PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343: 457-462, 2000
29. Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci PM, Cattaneo M: Multicenter study of homocysteine measurement-performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost 85: 291-295, 2001
30. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR: The Leiden Thrombophilia Study. Thromb Haemost 78: 631-635, 1997
31. Rodeghiero F, Tosetto A: The epidemiology of inherited thrombophilia: The VITA Project. Thromb Haemost 78: 636-640, 1997
32. Brown K, Luddington R, Williamson D, Baker P, Baglin T: Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol 98: 907-909, 1997
33. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334: 759-762, 1996
34. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V, Benedetti L, Girolami A: Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost 76: 883-886, 1996
35. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-17, 2004
36. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 42: 1309-1311, 1999
37. McNeil HP, Chesterman CN, Krilis SA: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49: 193-280, 1991
38. Franco RF, Middeldorp S, Meinardi JR, van Pampus EC, Reitsma PH: Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. Br J Haematol 111: 118-121, 2000
39. van Hylckama Vlieg A, Komanasin N, Ariens RA, Poort SR, Grant PJ, Bertina RM, Rosendaal FR: Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 119: 169-175, 2002
40. Crowther MA, Kelton JG: Congenital thrombophilic states associated with venous thrombosis: A qualitative overview and proposed classification system. Ann Intern Med 138: 128-134, 2003
41. May RE, Himmelfarb J, Yenicesu M, Knights S, Ikizler TA, Schulman G, Hernanz-Schulman M, Shyr Y, Hakim RM: Predictive measures of vascular access thrombosis: A prospective study. Kidney Int 52: 1656-1662, 1997
42. Van Cott EM, Laposata M: Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 12: 1141-1166, 1998
43. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G: Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322: 1494-1499, 1990
44. Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, Poli D, Fedi S, Abbate R, Frisco D: Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 115: 601-605, 2003
45. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881, 1992
46. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol 13: 2331-2337, 2002
47. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN, Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313-2321, 2003
48. Hennekens C, Buring J: Case-control studies. In: Epidemiology in Medicine, 1st Ed., edited by Mayrent SL, Boston, Little, Brown, 1987, pp 132-152